Shots:
- The EC has approved Onerji (levodopa/carbidopa) infusion for advanced PD pts with uncontrolled motor fluctuations. The therapy is being developed by its wholly owned subsidiary, NeuroDerm
- Approval was based on the global P-III (BouNDless) trial, which demonstrated Onerji + supplemental oral LD/CD significantly increased ON time without troublesome dyskinesia and reduced OFF time vs immediate-release oral LD/CD. Favourable long-term safety and tolerability results were also observed in the late P-II (BeyoND) study
- Onerji is a 24-hour continuous SC liquid LD/CD infusion therapy for advanced PD pts with motor fluctuations. Delivered via a portable infusion pump system, it is designed to maintain stable LD plasma concentrations and improve PK profiles
Ref: X4 Pharmaceuticals | Image: X4 Pharmaceuticals | Press Release
Related News: X4 Pharmaceuticals’ Xolremdi Receives the EC’s Approval for WHIM Syndrome
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
